Moleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100%
Independent research shows 2-DG activity against virus that causes COVID-19HOUSTON, April 8, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today...
Moleculin Announces Additional Positive Safety Data in EU AML Trial
A Total of 19 Patients Now Have Shown No Signs of CardiotoxicityHOUSTON, April 2, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly...
Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate
HOUSTON, March 20, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that a new patent application has...
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2019
HOUSTON, March 19, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced its financial results for the year ended...
Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus
Independent research suggests new approach to inhibiting the viral replication capability of a range of viruses, including CoronavirusHOUSTON, March 17, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical...
Moleculin Announces Dr. Hongbo Zhai Joins Science Advisory Board
To explore oncologic, dermatologic and viral opportunities for Moleculin's drug portfolio in ChinaHOUSTON, March 10, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...
Moleculin Issues Video Shareholder Letter
HOUSTON, March 4, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today issued a video letter to its shareholders from...
Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date
Supports Moleculin's Claim that Annamycin is a "Next Generation" AnthracyclineHOUSTON, Feb. 20, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...
Moleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions
Data Presented at the 4th Annual World Congress of Cutaneous Lymphomas in BarcelonaHOUSTON, Feb. 18, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...
Moleculin Announces $6.0 Million Registered Direct Offering
HOUSTON, Feb. 6, 2020 -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has entered into definitive...